1
0
0
News
NEC and VAXIMM collaborate on neoantigen cancer ...Drug Discovery News
www.drugdiscoverynews.com
... Heinz Lubenau, Ph.D., chief operating officer and co-founder of VAXIMM. “Individualized therapy is at the cutting edge of cancer treatment today, and, with Heinz Lubenau, Ph.D., chief operating officer and co-founder of VAXIMM. “Individualized therapy is at the cutting edge of cancer treatment today, and, with ...
VAXIMM Announces Presentations at ASCO and ...EQS News
www.eqs-news.com
Heinz Lubenau, Chief Operating Officer of VAXIMM, will give a corporate presentation. The Company will also host one-on-one meetings at this event. To ... Heinz Lubenau, Chief Operating Officer of VAXIMM, will give a corporate presentation. The Company will also host one-on-one meetings at this event. To ...
搜索X-MOL
newsletter.x-mol.com
... Heinz Lubenau 6 , Marco Springer 6 , Sébastien Wieckowski 7 , Klaus M Breiner 7 , Gerd Mikus 2 , Markus W Büchler 1 , Anne-Valerie Keller 6 , Ruhan Koc Heinz Lubenau 6 , Marco Springer 6 , Sébastien Wieckowski 7 , Klaus M Breiner 7 , Gerd Mikus 2 , Markus W Büchler 1 , Anne-Valerie Keller 6 , Ruhan Koc
NEC OncoImmunity Acquires VAXIMM's Neoantigen ...NEC Global
www.nec.com
— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, "We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...
Netzwerk-Profile
LinkedIn: Heinz Lubenau | LinkedIn
Heinz Lubenaus berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie Heinz Lubenau dabei hilft, ...
Heinz Lubenau Vaximm GmbH [LSA] Life-Sciences-Asia.com - The ...life-sciences-asia.com
www.life-sciences-asia.com
Heinz Lubenau (Vaximm GmbH). Lubenau, Heinz (Vaximm Managing Director Vaximm GmbH before BioGeneriX before Servier). Organisation, Vaximm ... Heinz Lubenau (Vaximm GmbH). Lubenau, Heinz (Vaximm Managing Director Vaximm GmbH before BioGeneriX before Servier). Organisation, Vaximm ...
LinkedIn: Heinz Lubenau | LinkedIn
Heinz Lubenau hat 9 Jobs im Profil angegeben. Sehen Sie sich auf LinkedIn das vollständige Profil an und erfahren Sie mehr über die Kontakte von Heinz Lubenau und über Jobs bei ähnlichen Unternehmen VAXIMM. Früher. VAXIMM,; BioGeneriX AG,; Servier Forschung und Pharmaentwicklung GmbH. Ausbildung.
Ontbrekend: sap
Interessen
NEC und VAXIMM kündigen Zusammenarbeit an, um ...
www.businesswire.com
— Dr. Heinz Lubenau, Chief Operating Officer und Mitbegründer von VAXIMM, sagte: „Wir freuen uns, diese Allianz mit NEC einzugehen und die ... › news › home
Heinz Lubenau - Patents
www.freshpatents.com
Recent bibliographic sampling of Heinz Lubenau patents listed/published in the public domain by the USPTO (USPTO Patent Application #,Title):
Neoantigen Targeted Therapies Market,
www.prnewswire.com
— Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM) All actual figures have been sourced and analyzed from publicly available ... › neo...
Management & Beteiligungen
Vaximm AG in Basel - Auskünfte | Moneyhouse
www.moneyhouse.ch
Vaximm AG in Basel ✓ aktiv ✓ Gegründet ✓ Management: Prof. Dr. Dr. Tomas Dezsö Szucs u.a ✓ Letzte Änderung: ✓
Business-Profile
Xing: Heinz Lubenau
Dr. / Chief Operating Officer / Mannheim / diabetes, Drug development and project management expertise, transition to clinical first-in-human trials, cardiology, national and European Scientific Advice experience, and hypertension., biosimilar development background
Thomas D. Szucs (BB Biotech AG)Life-Sciences-Europe.com
www.life-sciences-europe.com
Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ... Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen programs through ...
patentbuddy: Heinz Lubenau
BIOGENERIX AG, Neustadt, DE
Firmen-Mitarbeiter
VAXIMM company portrait | VAXIMM
vaximm.com
Management Team VAXIMM has a strong management team of experienced leaders with outstanding scientific knowledge and medical development expertise. Supervisory
VAXIMM company portrait
vaximm.com
Dr. Heinz Lubenau hat VAXIMM im Jahr mitgegründet Im Jahr begann er bei Servier und übernahm die Funktion des Clinical Research Manager und ... › ueber-uns
Private Homepages
About 14ᵗʰ ELSF - Sachs Eventssachsevent.com
sachsevent.com
... Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting Heinz Lubenau. Co-Founder & CEO, VAXIMM. Helen Chen. Global Sector Co-Head, Healthcare & Life Sciences | Greater China Managing Partner , L.E.K. Consulting.
Impressum | VAXIMM
vaximm.com
VAXIMM AG Technologiepark Basel . CH Basel Schweiz. Verwaltungsratspräsident: Dr. Thomas Hecht. VAXIMM GmbH. MAFINEX-Technologiezentrum Mannheim Deutschland. Geschäftsführer: Dr. Heinz Lubenau. . HRB
Besitz
Búsqueda en las colecciones de patentes nacionales e ...WIPO - Search International and National Patent Collections
patentscope.wipo.int
... Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic Heinz LUBENAU. The present invention relates to a DNA vaccine comprising a Salmonella typhi Ty21a strain comprising a DNA molecule comprising a eukaryotic ...
US DNA vaccine for use in pancreatic cancer patients
patentscope.wipo.int
This patent search tool allows you not only to search the PCT database of about 2 million International Applications but also the worldwide patent collections....
Bücher
Full article: ProfileTaylor & Francis Online
www.tandfonline.com
von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ... von K Breiner · — Klaus Breiner is the Executive Chairman, and Dr. Heinz Lubenau, General Manager of VAXIMMVAXIMM was formed in as a joint venture of BB Biotech Ventures ...
heiBIB: Leowardi-Bauer, Christine
katalog.ub.uni-heidelberg.de
... Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer, Tobias Friedrich, Heinz Lubenau, Marco Springer, Klaus M. Breiner, Gerd Mikus ...
Dokumente zum Namen
Abstract B196: Live attenuated oral Salmonella platform for ...aacrjournals.org
aacrjournals.org
von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar. von S Wieckowski · — ... Heinz Lubenau. Heinz Lubenau. 2Vaximm GmbH, Mannheim, Germany;. Search for other works by this author on: This Site · PubMed · Google Scholar.
AbstractAmerican Society of Clinical Oncology
meetings.asco.org
... Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany Heinz Lubenau, Michael Platten. Organizations. National Center for Tumor Diseases (NCT), UKHD and German Cancer Research Center (DKFZ), Heidelberg, Germany ...
AbstractAmerican Society of Clinical Oncology (ASCO)
meetings.asco.org
... Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip Heinz Lubenau, Marco Springer, Klaus M. Breiner, Nicolas Hohmann, Walter E. Haefeli, Gerd Mikus, Juergen Weitz, Alexis Ulrich, Markus W. Büchler, Philip ...
Wissenschaftliche Veröffentlichungen
Patents Assigned to Ratiopharm GmbHJustia
patents.justia.com
Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ... Inventors: Walter Hinderer, Heinz Lubenau. BIS-MMF DERIVATIVES. Publication number: Abstract: The present invention relates to novel compounds ...
GlycoPEGylated Filgrastim XM22 Demonstrates Dose ...ScienceDirect.com
www.sciencedirect.com
von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ... von H Lubenau · — Heinz Lubenau, PhD,1* Rolf Pokorny, MD,2* Luis Lopez-Lazaro, MD,2* Peter Bias, MD,3* Bruce Wallin, MD,4* Walter Hinderer, PhD,1* Anne-Katrin Maly,1* Michael ...
Double-blind, placebo-controlled first in human study to ...BMC Cancer
bmccancer.biomedcentral.com
von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ... von AG Niethammer · · Zitiert von: 68 — Authors and Affiliations. Vaximm, Mannheim, Germany. Andreas G Niethammer, Heinz Lubenau & Marco Springer. Clinical Pharmacology and ...
Patents Assigned to VAXIMM GMBHJustia
patents.justia.com
Inventors: Marco Springer, Heinz Lubenau. NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY. Publication number: Abstract: The present ... Inventors: Marco Springer, Heinz Lubenau. NOVEL MSLN TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY. Publication number: Abstract: The present ...
Veröffentlichungen allgemein
pdfSpringer
link.springer.com
von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany von H Lubenau · · Zitiert von: 74 — Heinz Lubenau,1 Peter Bias,2 Anne-Katrin Maly,1 Karl Ernst Siegler3 and Kai Mehltretter4. 1 BioGeneriX AG, Mannheim, Germany. 2 Merckle GmbH, Ulm, Germany
Questionaire for VAXIMM: Interview with Dr. Klaus Breiner ...ResearchGate
www.researchgate.net
— Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September — Klaus Breiner, Executive Chairman, and Dr. Heinz Lubenau, General Manager ... Heinz Lubenau, General Manager. Taylor & Francis. September
NEC OncoImmunity Acquires VAXIMM's Neoantigen ...Sunstone Life Science Ventures
sunstone.eu
— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC. OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC. OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...
Double-blind, placebo-controlled first in human study to investigate...
link.springer.com
... contains supplementary material, which is available to authorized users. Andreas G Niethammer, Heinz Lubenau contributed equally to this work.
Artikel & Meinungen
12th ANNUAL EUROPEAN LIFE SCIENCES CEO FORUMGenSearch
www.gensearch-consulting.com
— Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital — Hartmut Ehrlich, CEO, ABIVAX; Heinz Lubenau, Chief Operating Officer, VAXIMM GmbH; Holger Reithinger, General Partner, Forbion Capital ...
Vaximm is using AI to develop cancer vaccinesBasel Area Business & Innovation
baselarea.swiss
— Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the — Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC's novel AI technology will enable not only the ...
BIOTECH IN EUROPE FORUM - PDF Free Download
businessdocbox.com
22 VAXIMM AG HEINZ LUBENAU COO Heinz Lubenau co-founded VAXIMM in and currently serves as Chief Operating Officer leading all the development activities of the Company. Prior to thishe was Global Project Manager Biosimilar G-CSF and Head of Preclinical and Clinical Development at BioGeneriX AG, ...
Sonstiges
NEC OncoImmunity Acquires VAXIMM's Neoantigen ...Yahoo Finance
finance.yahoo.com
— Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen — Heinz Lubenau, CEO and Co-founder of VAXIMM, said, “We believe that NEC OncoImmunity is the ideal company to take VAXIMM's novel neoantigen ...
Dr. Heinz Lubenau ArchivesMedtech Alert
medtechalert.com
Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ... Heinz Lubenau. Top Post. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA · Experimental Cancer Drug May Slow Inflammation Linked to ...
Heinz Lubenau - Chief Drug Development OfficerThe Org
theorg.com
Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ... Heinz Lubenau. HL. Heinz Lubenau. Chief Drug Development Officer at NEC OncoImmunity AS. Show contact. Heinz Lubenau has an extensive work experience in the ...
Heinz Lubenau Email Address & Phone NumberAeroLeads
aeroleads.com
Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority. Get Heinz Lubenau information like Emails, Phone Number, Company, Colleagues, Competitors, Peers, Interests, Skills, Seniority.
6th Neoantigen Summit Europeinicop
www.inicop.org
... Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of Heinz Lubenau, Chief Drug Development Officer, NEC OncoImmunity, Kaidre Bendjama, Director, Personalized Vaccine, Transgene, Katherine Schultheis, Head of ...
Advancing Cancer Vaccines to Move to the Forefront of ...Allucent
www.allucent.com
Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ... Heinz-Lubenau.jpeg. Heinz Lubenau, PhD – Chief Executive Officer & Co-Founder VAXIMM ; Katka-Franke.jpeg. Katka Franke, PharmD PhD – Oncology Drug Development ...
Double-blind, placebo-controlled first in human study to ...National Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ... von AG Niethammer · · Zitiert von: 68 — doi: Authors. Andreas G Niethammer , Heinz Lubenau, ...
Invited Speakers - Living Materials 2020livingmaterials2020.de
www.livingmaterials2020.de
, Paul-Ehrlich-Institut, Langen, Germany. Heinz Lubenau, VAXIMM GmbH, Mannheim, Germany. Marjan de Mey, Ghent University, Belgium. Anne S. Meyer, University of ... , Paul-Ehrlich-Institut, Langen, Germany. Heinz Lubenau, VAXIMM GmbH, Mannheim, Germany. Marjan de Mey, Ghent University, Belgium. Anne S. Meyer, University of ...
Live attenuated oral Salmonella platform for effective TASCO Publications
ascopubs.org
von S Wieckowski · · Zitiert von: 1 — ... Heinz Lubenau Show FewerAuthors Info & Affiliations. Publication: Journal of Clinical Oncology. Volume 36, Number 5_suppl · https://doi.org JCO von S Wieckowski · · Zitiert von: 1 — ... Heinz Lubenau Show FewerAuthors Info & Affiliations. Publication: Journal of Clinical Oncology. Volume 36, Number 5_suppl · https://doi.org JCO
Neoantigen Targeted Therapies Market Holdexholdex.io
holdex.io
· Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM. Key companies covered in the report. · Bavarian Nordic. · Genocea Biosciences. · Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM. Key companies covered in the report. · Bavarian Nordic. · Genocea Biosciences.
Profile: VAXIMMNational Institutes of Health (NIH) (.gov)
pubmed.ncbi.nlm.nih.gov
von K Breiner · — Hum Vaccin Immunother Nov;9(11): doi: hv Epub Sep 16. Authors. Klaus Breiner , Heinz Lubenau. Affiliation. von K Breiner · — Hum Vaccin Immunother Nov;9(11): doi: hv Epub Sep 16. Authors. Klaus Breiner , Heinz Lubenau. Affiliation.
Related PatentsPaper Digest
www.paperdigest.org
HEINZ LUBENAU et. al. NEC ONCOIMMUNITYCOMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 · Summary Related Patents View Abstract: The present ... HEINZ LUBENAU et. al. NEC ONCOIMMUNITYCOMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 · Summary Related Patents View Abstract: The present ...
Richard Stratford - CEO & Co-FounderThe Org
theorg.com
Heinz Lubenau. Chief Drug Development Officer · Saverio Niccolini's profile picture. Saverio Niccolini. Chief Operating Officer. View in org chart. Timeline. Heinz Lubenau. Chief Drug Development Officer · Saverio Niccolini's profile picture. Saverio Niccolini. Chief Operating Officer. View in org chart. Timeline.
VAXIMM - Crunchbase Company Profile & FundingCrunchbase
www.crunchbase.com
... Date 2008; Founders Andreas Niethammer, Heinz Lubenau, Klaus Breiner; Operating Status Active; Last Funding Type Grant; Legal Name Vaximm AG. Company Type Date 2008; Founders Andreas Niethammer, Heinz Lubenau, Klaus Breiner; Operating Status Active; Last Funding Type Grant; Legal Name Vaximm AG. Company Type ...
VAXIMM Announces Regional Development and ...BioPharma Dive
www.biopharmadive.com
— Contact: VAXIMM AG Dr. Heinz Lubenau Tel.: + Media Inquiries: MC Services AG. Katja Arnold, Laurie — Contact: VAXIMM AG Dr. Heinz Lubenau Tel.: + Media Inquiries: MC Services AG. Katja Arnold, Laurie ...
VAXIMM CEO and Key Executive Team - Craft.cocraft.co
craft.co
VAXIMM's Chief Executive Officer & Co-Founder is Heinz Lubenau. Other executives include Thomas D. Szucs, Chairman; Marc Mansour, Chief Scientific Officer ... VAXIMM's Chief Executive Officer & Co-Founder is Heinz Lubenau. Other executives include Thomas D. Szucs, Chairman; Marc Mansour, Chief Scientific Officer ...
VAXIMM: From Basel to Mannheim to OsloSubstack · FrauHodl’s Substackvor 1 Jahr
frauhodl.substack.com
Heinz Lubenau. Dr. Heinz Lubenau, General Manager and Head of Development at VAXIMM GmbH. Link to Healthcaree Industry Baden-Württemberg ... Heinz Lubenau. Dr. Heinz Lubenau, General Manager and Head of Development at VAXIMM GmbH. Link to Healthcaree Industry Baden-Württemberg ...
Vaximm AG, Basel, SchweizNorth Data
www.northdata.de
Mitglied des Verwaltungsrats: Heinz Lubenau · Prokura: Heinz Lubenau · Präsident des Verwaltungsrats: Klaus Breiner · Prokura: Klaus Breiner ... Mitglied des Verwaltungsrats: Heinz Lubenau · Prokura: Heinz Lubenau · Präsident des Verwaltungsrats: Klaus Breiner · Prokura: Klaus Breiner ...
XM02, the First Biosimilar G-CSF, is Safe and Effective in ...Journal of Thoracic Oncology
www.jto.org
... Heinz Lubenau, PhD, Auro Del Giglio, MD. Journal of Thoracic Oncology. Volume 4 Issue 6 Pages (June 2009). DOI: JTO.0b013e3181a Copyright Heinz Lubenau, PhD, Auro Del Giglio, MD. Journal of Thoracic Oncology. Volume 4 Issue 6 Pages (June 2009). DOI: JTO.0b013e3181a Copyright ...
single-blind, randomized, crossover ...Gale
go.gale.com
von H Lubenau · · Zitiert von: 74 — Gale Academic OneFile includes Pharmacokinetic and pharmacodynamic profile of new bios by Heinz Lubenau, Peter Bias, Anne-Katrin . Click to explore. von H Lubenau · · Zitiert von: 74 — Gale Academic OneFile includes Pharmacokinetic and pharmacodynamic profile of new bios by Heinz Lubenau, Peter Bias, Anne-Katrin . Click to explore.
sortiert nach Relevanz / Datum